[Antineoplastic drug induced nausea and vomiting: What is the clinical practice in 2018? An update of AFSOS clinical guidelines].

{"article_title":"[Antineoplastic drug induced nausea and vomiting: What is the clinical practice in 2018? An update of AFSOS clinical guidelines].","author":"Jovenin N, Eche-Gass A, Ch\u00e8ze S, Launay-Vacher V, Mayeur D, Rey JB, Joly F, Krakowski I, Scott\u00e9 F","journal_title":"Bulletin du cancer","issn":"1769-6917","isbn":"","publication_date":"2019-05-01","volume":"106","issue":"5","first_page":"497","page_count":"","accession_number":"30922554","doi":"10.1016\/j.bulcan.2019.02.002","publisher":"Elsevier","doctype":"Journal Article","subjects":"Antineoplastic Agents adverse effects; Nausea chemically induced; Nausea prevention & control; Vomiting chemically induced; Vomiting prevention & control; Humans","interest_area":["Oncology"],"abstract":"Antineoplastic drug induced nausea and vomiting (ANDINV) (previously named: Chemotherapy-induced nausea and vomiting [CINV]) are one of the most feared adverse effect for patients who begin treatment with anti-cancer treatments and their bad control have a negative impact in the management of these patients. In this review article, it is proposed an update of French-speaking Association for oncologic supportive care (AFSOS) clinical practice of CINV guidelines. This update became necessary for several reasons: newly available anti-emetic drugs; new data published about individual risk factors of CINV; new antineoplastic agents available; changing in emetic risk levels for some molecules in the international guidelines. To address these guidelines, the various clinical presentations of ANDINV and their intensity classification are discussed. Then, the different therapeutic solutions are presented: classes of conventional drug therapies, complementary therapies and advice to patients. Then, the implementation of primary prophylaxis are presented in four steps: (1) to evaluate the emetic risk level of antineoplastic agent; (2) to set the emetic risk level of antineoplastic protocols; (3) to set types of antiemetic drugs to implement; (4) \"Outperform\" prophylaxis in case of individual risk factors. Finally, implementation of secondary prophylaxis and rescue treatments are adressed. Copyright \u00a9 2019 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=30922554","isPdfLink":false,"isSAML":false,"an":"30922554","number_other":"","type_pub":"","issn_electronic":"1769-6917","languages":"French","language":"fre","date_entry":"Date Created: 20190330 Date Completed: 20190606 Latest Revision: 20190606","date_update":"20240105","titleSource":"Bulletin du cancer [Bull Cancer] 2019 May; Vol. 106 (5), pp. 497-509. Date of Electronic Publication: 2019 Mar 25.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2019-05-01","description":"Antineoplastic drug induced nausea and vomiting (ANDINV) (previously named: Chemotherapy-induced nausea and vomiting [CINV]) are one of the most feared adverse effect for patients who begin treatment with anti-cancer treatments and their bad control have a negative impact in the management of these patients. In this review article, it is proposed an update of French-speaking Association for oncologic supportive care (AFSOS) clinical practice of CINV guidelines. This update became necessary for several reasons: newly available anti-emetic drugs; new data published about individual risk factors of CINV; new antineoplastic agents available; changing in emetic risk levels for some molecules in the international guidelines. To address these guidelines, the various clinical presentations of ANDINV and their intensity classification are discussed. Then, the different therapeutic solutions are presented: classes of conventional drug therapies, complementary therapies and advice to patients. Then, the implementation of primary prophylaxis are presented in four steps: (1) to evaluate the emetic risk level of antineoplastic agent; (2) to set the emetic risk level of antineoplastic protocols; (3) to set types of antiemetic drugs to implement; (4) "Outperform" prophylaxis in case of individual risk factors. Finally, implementation of secondary prophylaxis and rescue treatments are adressed.<br \/> (Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&scope=site&db=mdl&AN=30922554&authtype=shib&custid=ns346513&group=main&profile=eds","no_of_pages":"","authored_by":"Jovenin N, Eche-Gass A, Ch\u00e8ze S, Launay-Vacher V, Mayeur D, Rey JB, Joly F, Krakowski I, Scott\u00e9 F"}